Remacemide: Current status and clinical applications

Expert Opinion on Investigational Drugs

Volumn 9, Issue 4, 2000, Pages 871-833

  Schachter, S C ^a   Tarsy, D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AR R 12495 AR; Epilepsy; Huntington's disease; Parkinson's disease; Remacemide; Stroke

Indexed keywords

ANTICONVULSIVE AGENT; AR R 12495; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REMACEMIDE; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AFFECTIVE NEUROSIS; ATAXIA; BEHAVIOR DISORDER; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DYSPEPSIA; EPILEPSY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; VERTIGO;

EID: 0034104663     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.4.871     Document Type: Review

References (91)